An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 156 participants.
Also called NCT01202058
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 156 participants
- Sponsor
- Registry
-
NCT01202058
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands, Spain, Switzerland
- Registry status
- Terminated
Technical summary
Registry record NCT01202058. Randomized; single masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
- Acronym
- NEVO II
- Condition
- Atherosclerotic Coronary Artery Disease
- Intervention (Device)
- NEVO™ Sirolimus-eluting Coronary Stent System
- Intervention (Device)
- XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
- Lead sponsor
- Cordis US Corp.
Record details
- Record id
cardio:ct-nct01202058- Content hash
dd4cef9d1b73ce04c9921e393e4304f5101b075b417b89a64498b63da5d05629